Biokinetics and radiation dosimetry for patients undergoing a glycerol tri[1-14C]oleate fat malabsorption breath test

Gunnarsson, Mikael; Stenström, Kristina; Leide-Svegborn, Sigrid; Faarinen, Mikko; Magnusson, Carl-Erik; Åberg, Magnus; Skog, Göran; Hellborg, Ragnar; Mattsson, Sören

doi:10.1016/s0969-8043(03)00051-4

Cited by 17 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, the turnover rate of organically bound iodine, also between other compartments, may be assumed to be faster (Leggett, 2015) with a transfer coefficient approximately 50% larger for the youngest ages. There are no data for 123 I-BMIPP covering longer time periods, but from studies on labelled fatty acids (Gunnarsson et al, 2003), one must assume uptake into body fat and, consequently, slow turnover of part of the administered activity.…”

Section: Age Dependencementioning

confidence: 99%

ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances

Mattsson¹,

Johansson²,

et al. 2015

View full text Add to dashboard Cite

This report provides a compendium of current information relating to radiation dose to patients, including biokinetic models, biokinetic data, dose coefficients for organ and tissue absorbed doses, and effective dose for major radiopharmaceuticals based on the radiation protection guidance given in Publication 60(ICRP, 1991). These data were mainly compiled from Publications 53, 80, and 106(ICRP, 1987, 1998, 2008), and related amendments and corrections. This report also includes new information for 82Rb-chloride, iodide (123I, 124I, 125I, and 131I) and 123I labeled 2ß-carbomethoxy 3ß-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (FPCIT).The coefficients tabulated in this publication will be superseded in due course by values calculated using new International Commission on Radiation Units and Measurements/International Commission on Radiological Protection adult and paediatric reference phantoms and Publication 103 methodology (ICRP,2007). The data presented in this report are intended for diagnostic nuclear medicine and not for therapeutic applications.

show abstract

Section: Age Dependencementioning

confidence: 99%

ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances

Mattsson¹,

Johansson²,

et al. 2015

View full text Add to dashboard Cite

show abstract

“…One method was adapted from the method of Gunnarsson et al (33) by using 2 perspex tubes; the first tube was filled with Drierite (Sigma), which is a material that traps water, and the second tube was filled with Ascarite II (Sigma), which is a material that traps carbon dioxide. Silica tubing attached the 2 perspex tubes together, and subjects were instructed to blow into the tubes through a plastic drinking straw.…”

Section: Breath Carbon Dioxidementioning

confidence: 99%

Lycopene bioavailability and metabolism in humans: an accelerator mass spectrometry study

Ross¹,

Vuong²,

Ruckle³

et al. 2011

The American Journal of Clinical Nutrition

View full text Add to dashboard Cite

show abstract

“…Glycerol tri[ 1–14 C]olein was administered to two male volunteers and expired air, urine and feces collected along with biopsy samples of abdominal fat [99]. Expired air accounted for 73 and 55% of the administered dose for the two subjects.…”

Section: Diagnosticsmentioning

confidence: 99%

Accelerator Mass Spectrometry-Enabled Studies: Current Status and Future Prospects

Arjomand

2010

Bioanalysis

View full text Add to dashboard Cite

Accelerator mass spectrometry is a detection platform with exceptional sensitivity compared with other bioanalytical platforms. Accelerator mass spectrometry (AMS) is widely used in archeology for radiocarbon dating applications. Early exploration of the biological and pharmaceutical applications of AMS began in the early 1990s. AMS has since demonstrated unique problem-solving ability in nutrition science, toxicology and pharmacology. AMS has also enabled the development of new applications, such as Phase 0 microdosing. Recent development of AMS-enabled applications has transformed this novelty research instrument to a valuable tool within the pharmaceutical industry. Although there is now greater awareness of AMS technology, recognition and appreciation of the range of AMS-enabled applications is still lacking, including study-design strategies. This review aims to provide further insight into the wide range of AMS-enabled applications. Examples of studies conducted over the past two decades will be presented, as well as prospects for the future of AMS.The Ebers papyrus, written in Egypt in the 16th Century BC, lists the extensive pharmacopeia of that civilization. Included in the writings are beer, turpentine, myrrh, juniper berries, poppy, lead, salt and crushed precious stones. Also included were products derived from animals, such as lizard's blood, swine teeth and goose grease. From ancient China comes evidence of that culture's extensive efforts to heal through the use of natural products. The Pen Tsao, or Great Herbal, comprised 40 volumes describing thousands of prescriptions [1].It is curious to note that the same techniques that established the age of these written artifacts are now being used to quantify the kinetics and distribution of the pharmacopeia of this civilization. Accelerator mass spectrometry (AMS) established itself as an indispensable tool in archeology and radiocarbon dating in the 1980s. This article summarizes two decades of AMS research applied to the biomedical and pharmaceutical fields, with special focus on radiocarbon-based AMS applications.For reprint orders, please contact reprints@future-science.com. Financial & competing interests disclosureThe author is employed by Accium BioSciences, a provider of accelerator mass spectrometry services to the pharmaceutical industry, where he has stock ownership, stock options and patents pending. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript. NIH Public Access Author ManuscriptBioanalysis. Author manuscript; available in PMC 2010 November 1. Published in final edited form as:Bioanalysis. 2010 ; 2(3): 519-541. NIH-PA Author ManuscriptNIH-PA ...

show abstract

Biokinetics and radiation dosimetry for patients undergoing a glycerol tri[1-14C]oleate fat malabsorption breath test

Cited by 17 publications

References 18 publications

ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances

ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances

Lycopene bioavailability and metabolism in humans: an accelerator mass spectrometry study

Accelerator Mass Spectrometry-Enabled Studies: Current Status and Future Prospects

Contact Info

Product

Resources

About